Fortrea Holdings (FTRE) Cash from Financing Activities (2022 - 2025)
Fortrea Holdings (FTRE) posted Cash from Financing Activities of -$75.7 million for Q4 2025, down 51.4% on a QoQ basis from -$50.0 million in Q3 2025, and down 6781.82% year-over-year from $1.1 million in Q4 2024.
Fortrea Holdings (FTRE) Cash from Financing Activities (2022 - 2025) Analysis & Trends
Fortrea Holdings' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at -$75.7 million for Q4 2025.
- Quarterly Cash from Financing Activities fell 6781.82% year-over-year to -$75.7 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$164.7 million (up 61.76% YoY) and the FY2025 annual result came in at -$76.3 million, up 84.67% from the prior year.
- Cash from Financing Activities was -$75.7 million for Q4 2025 at Fortrea Holdings, down from -$50.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $88.4 million in Q1 2025 and bottomed at -$504.0 million in Q2 2024.
- A 4-year average of -$54.8 million and a median of -$10.8 million in 2023 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 315.02% in 2025, while the deepest fall reached 6781.82% in 2025.
- Fortrea Holdings' Cash from Financing Activities stood at -$5.9 million in 2022, then sank by 30.51% to -$7.7 million in 2023, then soared by 85.71% to -$1.1 million in 2024, then sank by 6781.82% to -$75.7 million in 2025.
- Business Quant data shows FTRE's Cash from Financing Activities at -$75.7 million in Q4 2025, -$50.0 million in Q3 2025, and -$39.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -75.70 Mn |
| Dec 31, 2025 | -75.70 Mn |
| Sep 30, 2025 | -50.00 Mn |
| Sep 30, 2025 | -50.00 Mn |
| Jun 30, 2025 | -39.00 Mn |
| Jun 30, 2025 | -39.00 Mn |
| Mar 31, 2025 | 88.40 Mn |
| Mar 31, 2025 | 88.40 Mn |
| Dec 31, 2024 | -1.10 Mn |
| Dec 31, 2024 | -1.10 Mn |
| Sep 30, 2024 | -14.00 Mn |
| Sep 30, 2024 | -14.00 Mn |
| Jun 30, 2024 | -504.00 Mn |
| Jun 30, 2024 | -504.00 Mn |
| Mar 31, 2024 | 21.30 Mn |
| Mar 31, 2024 | 21.30 Mn |
| Dec 31, 2023 | -7.70 Mn |
| Dec 31, 2023 | -7.70 Mn |
| Sep 30, 2023 | -7.70 Mn |
| Sep 30, 2023 | -7.70 Mn |